American Journal of Obstetrics & Gynecology
Volume 197, Issue 3, Supplement , Pages S56-S63 , September 2007

Use of single-dose nevirapine for the prevention of mother-to-child transmission of HIV-1: does development of resistance matter?

  • Michelle S. McConnell, MD

      Affiliations

    • Thailand–US Centers for Disease Control and Prevention Collaboration, Nonthaburi, Thailand
    • Division of Global AIDS, Centers for Disease Control and Prevention, Atlanta, GA
    • Corresponding Author InformationReprints: Michelle S. McConnell, MD, TUC, Ministry of Public Health, Tivanon Road, Nonthaburi, 11000, Thailand.
    • ,
  • Jeffrey S.A. Stringer, MD

      Affiliations

    • Schools of Medicine and Public Health, University of Alabama at Birmingham, Birmingham, AL
    • ,
  • Athena P. Kourtis, MD, PhD, MPH

      Affiliations

    • Division of Reproductive Health, Centers for Disease Control and Prevention, Atlanta, GA
    • ,
  • Paul J. Weidle, PharmD, MPH

      Affiliations

    • Division of HIV/AIDS, Centers for Disease Control and Prevention, Atlanta, GA
    • ,
  • Susan H. Eshleman, MD, PhD

      Affiliations

    • Johns Hopkins University, Baltimore, MD.

Received 15 December 2006 ,Accepted 26 February 2007.

References 

  1. World Health Organization. AIDS epidemic update December 2005. Last accessed: May 6, 2006. Available from: http://www.who.int/hiv/epiupdates/en/index.html 5.
  2. Anema A, Chan K, McGuire A, Barer JM, Hogg RS. Is “3 by 5” enough? (Recalculating the global need for antiretroviral treatment). Lancet. 2004;364:1034–1035
  3. UNAIDS. Global summary of the AIDS epidemic: December 2005. Last accessed: May 26, 2006. Available from: http://www.unaids.org/epi/2005/doc/EPIupdate2005_pdf_en/Epi05_02_en.pdf.
  4. US Department of Health and Human Services. Public Health Service task force recommendations for use of antiretroviral drugs in pregnant HIV-1 infected women for maternal health and interventions to reduce perinatal HIV-1 transmission in the United States. Last accessed: January 29, 2007. Available from: http://www.aidsinfo.nih.gov/ContentFiles/PerinatalGL.pdf.
  5. US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Last accessed: January 29, 2007. Available from: http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.
  6. McIntyre J. Preventing mother-to-child transmission of HIV: successes and challenges. BJOG. 2005;112:1196–1203
  7. Guay LA, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet. 1999;354:795–802
  8. Jackson JB, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial. Lancet. 2003;362:859–868
  9. Dabis F, Bequet L, Ekouevi DK, et al. Field efficacy of zidovudine, lamivudine and single-dose nevirapine to prevent peripartum HIV transmission. AIDS. 2005;19:309–318
  10. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment: Pediatric AIDS Clinical Trials Group Protocol 076 study group. N Engl J Med. 1994;331:1173–1180
  11. Lallemant M, Jourdain G, Le Coeur S, et al. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med. 2004;351:217–228
  12. Leroy V, Sakarovitch C, Cortina-Borja M, et al. Is there a difference in the efficacy of peripartum antiretroviral regimens in reducing mother-to-child transmission of HIV in Africa?. AIDS. 2005;19:1865–1875
  13. The Petra Study Team. Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomised, double-blind, placebo-controlled trial. Lancet. 2002;359:1178–1186
  14. De Cock KM, Fowler MG, Mercier E, et al. Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice. JAMA. 2000;283:1175–1182
  15. World Health Organization. Antiretroviral drugs and the prevention of mother-to-child transmission of HIV infection in resource-limited settings: Report of a technical consultation. Last accessed: May 2, 2006. Available from: http://www.who.int/reproductive-health/stis/docs/arvddrugsmeetingreport.pdf.
  16. World Health Organization. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants in resource-limited settings: towards universal access. Last accessed: September 6, 2006. Available from: http://www.who.int/hiv/pub/guidelines/pmtct/en/index.html.
  17. Eshleman SH, Mracna M, Guay LA, et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012). AIDS. 2001;15:1951–1957
  18. Palmer S, Boltz V, Martinson N, et al. Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy for prevention of maternal-to-fetal HIV-1 transmission. Proc Natl Acad Sci U S A. 2006;103:7094–7099
  19. Jourdain G, Ngo-Giang-Huong N, Le Coeur S, et al. Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy. N Engl J Med. 2004;351:229–240
  20. Chalermchokcharoenkit A, Asavapiriyanont S, Teeraratkul A, et al. Combination short-course zidovudine plus 2-dose nevirapine for prevention of mother-to-child transmission: safety, tolerance, transmission, and resistance results. [abstract] In: Presented at the 11th Conference on Retroviruses and Opportunistic Infections, February, San Francisco, CA.. 2004;
  21. Cunningham CK, Chaix ML, Rekacewicz C, et al. Development of resistance mutations in women receiving standard antiretroviral therapy who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 316. J Infect Dis. 2002;186:181–188
  22. Fowler MG, Mofenson L, McConnell M. The interface of perinatal HIV prevention, antiretroviral drug resistance, and antiretroviral treatment: what do we really know?. J Acquir Immune Defic Syndr. 2003;34:308–311
  23. World Health Organization. What’s new in the revised ART guidelines for adults and adolescents. Last accessed: May 2, 2006. Available from: http://www.who.int/hiv/mediacentre/fs_2006guidelines_art/en.
  24. Eshleman SH, Hoover DR, Chen S, et al. Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP. J Infect Dis. 2005;192:30–36
  25. Gordon M, Graham N, Bland R, et al. Surveillance of resistance in KZN South Africa, including mother-infant pairs 6 weeks after single-dose NVP. Antivir Ther. 2004;9:S80
  26. Kantor R, Lee E, Johnston E, et al. Rapid flux in non-nucleoside reverse transcriptase inhibitor resistance mutations among subtype C HIV-1-infected women after single dose nevirapine. Antivir Ther. 2003;8:S85
  27. Havlir DV, Eastman S, Gamst A, Richman DD. Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients. J Virol. 1996;70:7894–7899
  28. Church JD, Hudelson SE, Guay LA, et al. HIV-1 variants with nevirapine resistance mutations are rarely detected in antiretroviral drug naïve African women with subtypes A, C, and D. AIDS Res Hum Retroviruses [In press].
  29. Cressey TR, Jourdain G, Lallemant MJ, et al. Persistence of nevirapine exposure during the postpartum period after intrapartum single-dose nevirapine in addition to zidovudine prophylaxis for the prevention of mother-to-child transmission of HIV-1. J Acquir Immune Defic Syndr. 2005;38:283–288
  30. Muro E, Droste JAH, ter Hofstede H, Bosch M, Dolmans W, Burger DM. Nevirapine plasma concentrations are still detectable after more than 2 weeks in the majority of women receiving single-dose nevirapine: implications for intervention studies. J Acquir Immune Defic Syndr. 2005;39:419–421
  31. Musoke P, Guay LA, Bagenda D, et al. A phase I/II study of the safety and pharmacokinetics of nevirapine in HIV-1-infected pregnant Ugandan women and their neonates (HIVNET 006). AIDS. 1999;13:479–486
  32. Eshleman SH, Becker-Pergola G, Deseyve M, et al. Impact of human immunodeficiency virus type 1 (HIV-1) subtype on women receiving single-dose nevirapine prophylaxis to prevent HIV-1 vertical transmission (HIV network for prevention trials 012 study). J Infect Dis. 2001;184:914–917
  33. Chaix ML, Ekouevi DK, Peytavin G, et al. Persistence of nevirapine-resistant virus and pharmacokinetic analysis in women who received intrapartum NVP associated to a short course of zidovudine (ZDV) to prevent perinatal HIV-1 transmission: the Ditrame Plus ANRS 1201/12 Study, Abidjan, Cote d’Ivoire. Antivir Ther. 2004;9:S176
  34. Jackson JB, Becker-Pergola G, Guay LA, et al. Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission. AIDS. 2000;14:F111–F115
  35. Flys T, Nissley DV, Claasen CW, et al. Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012. J Infect Dis. 2005;192:24–29
  36. Flys TS, Jones DC, Chen S, et al. Quantitative analysis of HIV-1 variants with the K103N resistance mutation after single dose nevirapine in women with HIV-1 subtypes A, C and D. J Acquir Immune Defic Syndr. 2006;42:610–613
  37. Johnson JA, Li JF, Morris L, et al. Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated. J Infect Dis. 2005;192:16–23
  38. Little SJ, Dawson K, Hellmann NS, Richman DD, Frost SDW. Persistence of transmitted drug-resistant virus among subjects with primary HIV infection deferring antiretroviral therapy. Antivir Ther. 2003;8:S129
  39. Palmer S, Boltz V, Maldarelli F, et al. Selection and persistence of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapy. AIDS. 2006;20:701–710
  40. Loubser S, Balfe P, Sherman G, Hammer S, Kuhn L, Morris L. Decay of K103N mutants in cellular DNA and plasma RNA after single-dose nevirapine to reduce mother-to-child HIV transmission. AIDS. 2006;20:995–1002
  41. Flys TS, Donnell D, Mwatha A, et al. Persistence of K103N-containing HIV-1 variants after single-dose nevirapine for prevention of mother-to-child transmission. J Infect Dis. 2007;195:711–715
  42. Eshleman SH, Hoover DR, Chen S, et al. Resistance after single-dose nevirapine prophylaxis emerges in a high proportion of Malawian newborns. AIDS. 2005;19:2167–2169
  43. Martinson NA, Morris L, Gray G, et al. Selection and persistence of viral resistance in HIV-infected children after exposure to single-dose nevirapine. J Acquir Immune Defic Syndr. 2006;Epub ahead of print
  44. Shapiro RL, Holland DT, Capparelli E, et al. Antiretroviral concentrations in breast-feeding infants of women in Botswana receiving antiretroviral treatment. J Infect Dis. 2005;192:720–727
  45. Chung MH, Kiarie JN, Richardson BA, Lehman DA, Overbaugh J, John-Stewart GC. Breast milk HIV-1 suppression and decreased transmission: a randomized trial comparing HIVNET 012 nevirapine versus short-course zidovudine. AIDS. 2005;19:1415–1422
  46. Lee EJ, Kantor R, Zijenah L, et al. Breast-milk shedding of drug-resistant HIV-1 subtype C in women exposed to single-dose nevirapine. J Infect Dis. 2005;192:1260–1264
  47. Lockman S, Shapiro RL, Smeaton LM, et al. Response to antiretroviral therapy after a single, peripartum dose of nevirapine. N Engl J Med. 2007;356:135–147
  48. Coovadia A, Marais B, Abrams E, et al. Virologic responses to NNRTI treatment among women who took single-dose nevirapine 18 to 36 months earlier. [abstract] In: Presented at the 13th Conference on Retroviruses and Opportunistic Infections, February, Denver, CO.. 2006;
  49. Zijenah L, Kadzirange G, Rusakaniko S, et al. Community-based generic ART following single-dose nevirapine or short-course zidovudine in Zimbabwe. In: Presented at the 13th Conference on Retroviruses and Opportunistic Infections, February, Denver, CO.. 2006;
  50. Bedikou G, Viho I, Towne-Gold B, et al. 6-month immunological response with HAART containing Nevirapine in HIV infected women post exposure to single dose of nevirapine for PMTCT: the MTCT-Plus Initiative in Abidjan, Cote d’Iviore (2003-2005). [abstract] In: Presented at the 3rd IAS Conference on HIV Pathogenesis and Treatment; July, Rio de Janeiro.. 2005;
  51. Chi BH, Sinkala M, Stringer EM, et al. Early clinical and immune response to NNRTI-based antiretroviral therapy among women exposed to single-dose nevirapine for prevention of mother-to-child HIV transmission. AIDS. 2007;21:957–964
  52. Eure C, Bakaki P, McConnell M, et al. Effectiveness of repeat single-dose nevirapinein subsequent pregnancies among Ugandan women. [abstract] In: Presented at the 13th Conference on Retroviruses and Opportunistic Infections, February, Denver, CO.. 2006;
  53. Martinson N, Ekouevi D, Gray G, et al. Effectiveness of single-dose nevirapine in consecutive pregnancies in Soweto and Abidjan. [abstract] In: Presented at the 13th Conference on Retroviruses and Opportunistic Infections, February, Denver, CO.. 2006;
  54. Gray G, McIntyre J, Hopley M, Martinson N, Hall D, Mayers D. NNRTI-resistance mutations in HIV-1 infected infants following single dose nevirapine (SD-NVP) are reduced by the addition of short course zidovudine and 3TC. [abstract] In: Presented at the 3rd IAS Conference on HIV Pathogenesis and Treatment, July, Rio de Janeiro.. 2005;
  55. McIntyre JA, Martinson N, Gray GE, et al. Addition of short course Combivir (CBV) to single dose Viramune (SDNVP) for the prevention of mother-to-child transmission (pMTCT) of HIV-1 can significantly decrease the subsequent development of maternal and paediatric NNRTI-resistant virus. [abstract] In: Presented at the 3rd IAS Conference on HIV Pathogenesis and Treatment, July, Rio de Janeiro.. 2005;
  56. Chaix ML, Ekouevi DK, Rouet F, et al. Low risk of nevirapine resistance mutations in the prevention of mother-to-child transmission of HIV-1: Agence Nationale de Recherches sur le SIDA Ditrame Plus, Abidjan, Cote d’Ivoire. J Infect Dis. 2006;193:482–487
  57. Doherty TM, McCoy D, Donohue S. Health system constraints to optimal coverage of the prevention of mother-to-child HIV transmission programme in South Africa: lessons from the implementation of the national pilot programme. Afr Health Sci. 2005;5:213–218
  58. Stringer JSA, Sinkala M, Maclean CC, et al. Effectiveness of a city-wide program to prevent mother-to-child HIV transmission in Lusaka, Zambia. AIDS. 2005;19:1309–1315
  59. Tarwireyi F. Implementation of the prevention of mother-to-child transmission of HIV programme in Zimbabwe: achievements and challenges. Cent Afr J Med. 2004;50:95–100
  60. Food and Drug Administration public health advisory for nevirapine (Viramune). Last accessed: May 3, 2006. Available from: http://www.fda.gov/cder/drug/advisory/nevirapine.htm.
  61. Hitti J, Frenkel LM, Stek AM, et al. Maternal toxicity with continuous nevirapine in pregnancy: results from PACTG 1022. J Acquir Immune Defic Syndr. 2004;36:772–776
  62. Marazzi MC, Germano P, Liotta G, et al. Safety of nevirpine-containing antiretroviral triple therapy regimens to prevent vertical transmission in an African cohort of HIV-1-infcted pregnant women. HIV Med. 2006;7:338–344
  63. Sanne I, Mommeja-Marin H, Hinkle J, et al. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis. 2005;191:825–829
  64. Thomas T, Amornkul P, Mwidau J, et al. Preliminary findings: Incidence of serious adverse events attributed to nevirapine among women enrolled in an ongoing trial using HAART to prevent mother-to-child HIV transmission. [abstract] In: Presented at the 12th Conference on Retroviruses and Opportunistic Infections, February, Boston, MA.. 2005;
  65. Timmermans S, Tempelman C, Godfried MH, et al. Nelfinavir and nevirapine side effects during pregnancy. AIDS. 2005;19:795–799
  66. Food and Drug Administration. Food and Drug Administration Report (FDA): important change in Sustiva (efavirenz) package insert. Last accessed May 3, 2006. Available from: http://www.fda.gov/medwatch/safety/2005/Sustiva_DHCPletter-061005.pdf.
  67. Palombi L, Germano P, Liotta G, et al. HAART in pregnancy: safety, effectiveness, and protection from viral resistance: results from the DREAM cohort. [abstract] In: Presented at the 12th Conference on Retroviruses and Opportunistic Infections, February, Boston, MA.. 2005;
  68. Lyons FE, Coughlan S, Byrne CM, Hopkins SM, Hall WW, Mulcahy FM. Emergence of antiretroviral resistance in HIV-positive women receiving combination antiretroviral therapy in pregnancy. AIDS. 2005;19:63–67

 The findings and conclusions in this report are those of the author(s) and do not necessarily represent the views of the US Centers for Disease Control and Prevention.

PII: S0002-9378(07)00267-0

doi: 10.1016/j.ajog.2007.02.031

American Journal of Obstetrics & Gynecology
Volume 197, Issue 3, Supplement , Pages S56-S63 , September 2007

Article Tools